Enhanced Metabolic Health and Immune Response with Bictegravir/emtricitabine/TAF: Insights from a 96‑week Retrospective Study

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), as a fixed dosed combination, is effective in people living with human immunodeficiency virus (PLWH) previously treated with other therapeutic regimens. The aim of the present retrospective observational real-life study was to analyze virological suppression and immunological, metabolic and safety profile of B/F/TAF. Data were collected from 127 PLHW who switched from any regimen to B/F/TAF. Viral load and virological suppression (viral load <50 copies/ml) were assessed by using real-time PCR methodologies; CD4 and CD8 T cell count as well as CD4/CD8 ratio were determined by cytofluorimetric analyses; other metabolic parameters such as total cholesterol, triglycerides, High- and Low-Density Lipoproteins were assessed by using immunoenzymatic assay. All of the aforementioned parameters were assessed at different timepoints (Baseline, 48 and 96 weeks) for the patients switching to B/F/TAF. Of 127 PLHW [96 (75.6%) male and 31 (24.4%) female, with a mean age of 46.8±10.7 years], 107 PLHW were included in the analysis. The percentage of virologically suppressed PLWH increased from 66.4 to 74.8% at 96 weeks. A statistically significant increase in absolute CD4 (P<0.0001) and CD8 T cell count (P=0.002) was observed. Of importance, there was a significant increase in CD4/CD8 ratio from 0.95 (0.52-1.31) to 1.16 (0.75-1.39) (P=0.003) after 96 weeks. There was a significant decrease in the median values of triglycerides (P<0.0001) and total cholesterol (P<0.0001). Serum creatinine showed a significant increase (P=0.0001). In real life, switching to B/F/T was safe and highly effective both virologically and immunologically. Decrease in cholesterol and triglyceride levels suggested a favorable metabolic profile, which may decrease inflammation, leading to a healthier state and less organ damage.

References

Sookoian S, Pirola C . Liver enzymes, metabolomics and genome-wide association studies: from systems biology to the personalized medicine. World J Gastroenterol. 2015; 21(3):711-25. PMC: 4299326. DOI: 10.3748/wjg.v21.i3.711. View

Marino A, Cosentino F, Ceccarelli M, Moscatt V, Pampaloni A, Scuderi D . Entecavir resistance in a patient with treatment-naïve HBV: A case report. Mol Clin Oncol. 2021; 14(6):113. PMC: 8060856. DOI: 10.3892/mco.2021.2275. View

Siest G, Schiele F, Galteau M, Panek E, Steinmetz J, Fagnani F . Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem. 1975; 21(8):1077-87. View

Serrano-Villar S, Wu K, Hunt P, Lok J, Ron R, Sainz T . Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events. EBioMedicine. 2022; 80:104072. PMC: 9156990. DOI: 10.1016/j.ebiom.2022.104072. View

Ron R, Martinez-Sanz J, Herrera S, Ramos-Ruperto L, Diez A, Sainz T . CD4/CD8 ratio and CD8+ T-cell count as prognostic markers for non-AIDS mortality in people living with HIV. A systematic review and meta-analysis. Front Immunol. 2024; 15:1343124. PMC: 10868578. DOI: 10.3389/fimmu.2024.1343124. View

Acosta R, Willkom M, Andreatta K, Liu H, Martin R, Parvangada A . Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. J Acquir Immune Defic Syndr. 2020; 85(3):363-371. DOI: 10.1097/QAI.0000000000002454. View

Helleberg M, May M, Ingle S, Dabis F, Reiss P, Fatkenheuer G . Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS. 2014; 29(2):221-9. PMC: 4284008. DOI: 10.1097/QAD.0000000000000540. View

Yamada J, Tomiyama H, Yambe M, Koji Y, Motobe K, Shiina K . Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. Atherosclerosis. 2006; 189(1):198-205. DOI: 10.1016/j.atherosclerosis.2005.11.036. View

Mujawar Z, Rose H, Morrow M, Pushkarsky T, Dubrovsky L, Mukhamedova N . Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 2006; 4(11):e365. PMC: 1629034. DOI: 10.1371/journal.pbio.0040365. View

10.

Favre D, Stoddart C, Emu B, Hoh R, Martin J, Hecht F . HIV disease progression correlates with the generation of dysfunctional naive CD8(low) T cells. Blood. 2011; 117(7):2189-99. PMC: 3062328. DOI: 10.1182/blood-2010-06-288035. View

11.

Lazzaro A, Bianchini D, Gentilini Cacciola E, Mezzaroma I, Falciano M, Andreoni C . Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort. Viruses. 2023; 15(6). PMC: 10302527. DOI: 10.3390/v15061222. View

12.

Ryom L, Mocroft A, Kirk O, Worm S, Kamara D, Reiss P . Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 2013; 207(9):1359-69. PMC: 3610424. DOI: 10.1093/infdis/jit043. View

13.

Chen L, Sun H, Chuang Y, Huang Y, Liu W, Lin K . Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide. J Microbiol Immunol Infect. 2023; 56(3):575-585. DOI: 10.1016/j.jmii.2023.01.015. View

14.

Klatzmann D, Barre-Sinoussi F, Nugeyre M, Danquet C, Vilmer E, Griscelli C . Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science. 1984; 225(4657):59-63. DOI: 10.1126/science.6328660. View

15.

Pottel H, Vrydags N, Mahieu B, Vandewynckele E, Croes K, Martens F . Establishing age/sex related serum creatinine reference intervals from hospital laboratory data based on different statistical methods. Clin Chim Acta. 2008; 396(1-2):49-55. DOI: 10.1016/j.cca.2008.06.017. View

16.

Ho D, Neumann A, Perelson A, Chen W, Leonard J, Markowitz M . Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995; 373(6510):123-6. DOI: 10.1038/373123a0. View

17.

Squillace N, Ricci E, Maggi P, Taramasso L, Menzaghi B, De Socio G . Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir. PLoS One. 2023; 18(8):e0289132. PMC: 10411741. DOI: 10.1371/journal.pone.0289132. View

18.

Marino A, Zafarana G, Ceccarelli M, Cosentino F, Moscatt V, Bruno G . Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience. Diagnostics (Basel). 2021; 11(12). PMC: 8700507. DOI: 10.3390/diagnostics11122336. View

19.

Lu L, Yang Y, Yang Z, Wu Y, Liu X, Li X . Altered plasma metabolites and inflammatory networks in HIV-1 infected patients with different immunological responses after long-term antiretroviral therapy. Front Immunol. 2023; 14:1254155. PMC: 10565217. DOI: 10.3389/fimmu.2023.1254155. View

20.

Lake J, Hyatt A, Feng H, Debroy P, Kettelhut A, Miao H . A Randomized Clinical Trial of Transgender Women Switching to B/F/TAF: The (mo)BETTA Trial. Open Forum Infect Dis. 2023; 10(4):ofad178. PMC: 10122488. DOI: 10.1093/ofid/ofad178. View